From Injections to Pills: Breaking Down the New Oral GLP-1 Data

Show Notes:In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable WegovyHow orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugsWhy these new therapies could make weight management more accessible and affordableThe fascinating pharmacology behind “snack molecules” and small-molecule receptor agonistsCommon misconceptions about bioavailability, dosing, and side effectsThe potential role of oral GLP-1s for patients with mild obesity or cardiometabolic diseaseWhether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.Oasis 1 Trial LinkOasis 4 Trial LinkAttain 1 Trial Link Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.